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Abstract  We present rare cases 
of three adverse drug events from 
artemeter-Lumefantrine(AL) in-
gestion. This is an antimalaria 
combination therapy used in the 
management of malaria. Adverse 
reaction is rarely reported when 
using this drug. 
We report these cases of our pa-
tients who developed urticaria and 
bullae. One had hypotension few 
hours after taking AL.  We report 
these cases to show that though 
rare, adverse drug event can occur 
in AL. 
Conclusion: Artemesinin combina-
tion therapy though safe in chil-
dren, is not without adverse reac-
tion.  
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Malaria is one of the most significant causes of morbid-
ity and mortality worldwide, causing approximately 
881,000 deaths every year .1 The current WHO guide-
lines for the treatment of malaria recommend the use of 
artemisinin-based combination therapy (ACT) owing to 
Plasmodium falciparum resistance to monotherapy .2 
Artemether/lumefantrine (AL) was the first fixed-dose 
combination of ACT to be approved by the European 
regulatory authorities according to the requirements of 
the International Committee on Harmonization (ICH). 
Artemether is derived from the Chinese herb sweet 
wormwood (Artemisua annua). The antimalarial proper-
ties of artemether stem from interference with parasite 
transport proteins, disruption of parasite mitochondrial 
function, inhibition of angiogenesis, and modulation f 
host immune function.3  Artemether is absorbed very 
rapidly after oral administration reaching peak plasm  
concentrations within 2 hours after dose .4,5 It has a half-
life of 1–3 hours. It is metabolized quickly via CYP450 
2B6, CYP450 3A4 and possibly CYP450 2A6 to the 
more potent antimalarial metabolite DHA, which in turn 
is converted to inactive metabolites primarily by glu-
curonidation via UGT1A1, 1A8/9 and 2B7.6 Artemether 
induces CYP450 2C19 and 3A4. These metabolites may 
be a major trigger for adverse reaction. 
 
Lumefantrine is an aryl-amino alcohol that prevents 
detoxification of heam, such that toxic heam and free 
radicals induce parasite death .7 Lumefantrine absorption 
occurs 2 hours after oral intake reaching peak plasma 
concentration after 3-4 hours .7 It has a half life of 3–6 
days and is responsible for preventing recurrent malaria 
parasitemia. Lumefantrine is metabolized by N-
debutylation mainly by CYP450 3A4  to desbutyl-
lumefantrine with 5–8-fold higher antiparasitic effect 
than lumefantrine. Lumefantrine inhibits CYP450 2D6 .8 
 
Adverse effects are rare.3 There have been case reports 
of neurological problems (including ataxia, nystagmus, 
tremor and slurred speech) occurring after administra-
tion of herbal artemisinin or artesunate monotherapy .9  
However, it is questionable whether these neurological 




YI is a 7 year old female who presented with fever and 
cough of 2 days duration. Fever was low grade and in-
termittent while cough was unproductive with no  
difficulty in breathing. An empirical diagnosis of  
Malaria was made, following this, mother gave TM 
(Ajanta pharma limited.MFD 07/2011.EXP 06/2013) 2 
tablets (40mg lumafanthrine+240mgartesunate), twice a 
day for 3 days(This is appropriate for child’s weight). 
Few hours after the first dose of the drug, she was found 
to have developed urticarial rashes on the face and bul-
lae on the lips. This rash was itchy and makes patient 
uncomfortable. There was slight wheeze and catarrh. 
Child had been treated with this drug before. There was 
no history of drug allergy. 
 
Examination revealed pyrexia (38oc), fast and rapid 
pulse (114 beats per minutes) and Blood pressure of 
80/50mmHg.  A diagnosis of adverse drug reaction was
made. The drug was withdrawn and she was commenced 
on Intravenous promethazine and hydrocortisone for 3 
days. The rash cleared, fever subsided and clinical s gns 
were stable three days after therapy. 
Case 2 
 
EK is a 3- year old male who presented in a clinic with a 
two days history of fever, vomiting, diarrhea and weak-
ness of 3 days duration. On examination, he was found 
to be lethargic but in no obvious respiratory distre s. 
Other findings were normal. He was diagnosed as acute  
uncomplicated malaria and then placed on Intravenous 
fluids and Intravenous Artesunate. Just few minutes 
later, we noted generalized urticarial rash and maculo-
papular rash. Vital signs were within normal ranges.  
A diagnosis of adverse drug reaction was made, and 
patient was placed on Intravenous hydrocortisone and 




B is a 3 month old male who presented with fever and
poor sucks at breast of three days duration. Systemic 
examination revealed no obvious abnormality. A tenta-
tive diagnosis of malaria was made. He was given intra-
muscular Artemerter, after which fever subsided. The  
parenteral drug was then changed to syrup P-alaxin 8mls
daily for three days. On the third day of commencement 
of this drug, baby was brought back to the hospital with 
an urticarial and maculopapular rash. Pulse rate then was 
142 beat per minute and respiratory rate was 68 cycles 
per minute (tachypnoea). The patient was managed with 
antihistamine and low dose steroid; he is doing well as 






Adverse drug reaction is an unpleasant reaction, which 
results from an intervention related to the use of a me-
dicinal product which predicts hazard from future ad-
ministration, and warrants prevention or a specific treat-
ment or alteration of the dosage regimen or withdrawal 
of product.9 
Adverse drug reactions caused by immune and nonim-
mune mechanisms are a major cause of morbidity and 
mortality worldwide. They are the most common iatro-
genic illness, complicating 5 to 15 percent of therapeutic 
drug courses.10 Three to six percent of all hospital ad-
missions are because of adverse drug reactions, and 6 to 
15 percent of hospitalized patients (2.2 million persons 
in the United States in 1994) experience a serious ad-
verse drug reaction.10 
 
The body’s response can affect many organ systems but 
the skin is the organ most frequently involved as seen in 
our patients.11 Symptoms of Artemeter -Lumafanthrine 
vary and could present as urticarial rash, itching, swell-
ing of the lips, wheezing, hives and systemic features as 
hypotension, fainting, palpitations etc. Our patients pre-
sented with uticarial rash, itching and swelling of the 
lips and hives but only one presented with hypotension. 
12 At times it can make the skin blister and peel: A phe-
nomenom called Toxic epidermal necrolysis(TEN).11 
None of our series presented with palpitations nor TEN. 
Combisunate is an artemether-lumefantrine derivative 
which side effects were mild, did not lead to artemether-
lumefantrine discontinuation, and can resolve. Hartz et 
al noted that artemether-lumefantrine 6-dose regimen 
was discontinued in 0.2% of adult patients due to side 
effects. He also noted few adverse effects in his serie .12 
Urticaria was reported in less than 3% of his patients. 
Serious skin reactions (bullous eruption) have been  
reported rarely during postmarketing experience.13 Neu-
rological deficits and ototoxicity have been reported in 
some cases of artemerter –Lumenfantrin ingestion.13 ur 
series had urticaria and a bullous eruption on their lips 
but no neurological deficits or hearing problems. The 
relationship between the drug intake and the onset of 
clinical symptoms is critical. Unless the patient has been 
previously sensitized to a drug, the interval betwen 
initiation of therapy and the onset of reaction is rarely 
less than one week or more than one month.11 Our first 
and second cases occurred few hours after initiation of 
therapy while the third occurred after two days. 
 
The most important measure in managing drug hyper-
sensitivity reactions is the discontinuation of theoffend-
ing medication.14 Alternative medications with unrelated 
chemical structures should be substituted when avail-
able. In the majority of patients, symptoms will resolve 
within two weeks if the diagnosis of drug hypersensitiv-
ity is correct.14 All the signs and symptoms resolved in 
one of our patients within minutes while the other two 
happened in just three days after treatment. Additional 
therapy for drug hypersensitivity reactions is largely 
supportive and symptomatic.11 Systemic corticosteroids 
may speed recovery (as in our patient) in some cases of 
rug hypersensitivity. 11  Topical corticosteroids and oral 
antihistamines may improve dermatologic symptoms. 







Artemether-lumefantrine combination can lead to minor 
skin related adverse events. 
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